Efficacy markers in depression.
Current antidepressant agents are similar in efficacy to the original drugs discovered in the 1950s. The development of new treatments for depression is, however, limited by the absence of validated human biomarker models to predict efficacy, clinical profile and dosing. Such models need to meet key...
Asıl Yazarlar: | Harmer, C, Cowen, P, Goodwin, G |
---|---|
Materyal Türü: | Journal article |
Dil: | English |
Baskı/Yayın Bilgisi: |
2011
|
Benzer Materyaller
-
Efficacy markers in depression
Yazar:: Harmer, C, ve diğerleri
Baskı/Yayın Bilgisi: (2011) -
Low-dose tryptophan depletion in recovered depressed patients induces changes in cognitive processing without depressive symptoms.
Yazar:: Hayward, G, ve diğerleri
Baskı/Yayın Bilgisi: (2005) -
Low-dose tryptophan depletion in recovered depressed patients induces changes in cognitive processing without depressive symptoms
Yazar:: Hayward, G, ve diğerleri
Baskı/Yayın Bilgisi: (2005) -
Normalization of enhanced fear recognition by acute SSRI treatment in subjects with a previous history of depression.
Yazar:: Bhagwagar, Z, ve diğerleri
Baskı/Yayın Bilgisi: (2004) -
Elevated waking cortisol levels in neuroticism: A biological vulnerability factor for depressive disorders?
Yazar:: Portella, M, ve diğerleri
Baskı/Yayın Bilgisi: (2004)